Redeye: Margin expansion ahead in Xvivo Perfusion

Sales in Q2 came in below our expectations, causing us to lower our sales estimates for H2'17. We still predict that 2018 will be the year of STEEN Solution, where a broader clinical acceptance and obtained reimbursement will drive strong sales growth.

Profitability in Q2 exceeded our expectations by a wide margin and expect to see strong margin expansion from the end of the year and onwards. Read the Research Update by Arvid Necander at:

Start following companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.